A21

A21 is an early preclinical **covalent venetoclax-dihydroartemisinin conjugate** developed as a next-generation antileukemia agent. It was generated by modifying the polyethylene glycol linker backbone of the preceding conjugate A20 with nitrogen-containing polar groups to improve aqueous solubility and inhibition of leukemic colony formation. The conjugate series is designed to retain venetoclax-like B-cell lymphoma 2 inhibition while addressing resistance associated with myeloid cell leukemia 1 and B-cell lymphoma-extra large expression in acute myeloid leukemia. ([aacrjournals.org](https://aacrjournals.org/cancerres/article/86/7_Supplement/7087/782072/Abstract-7087-Optimizing-the-linker-of-venetoclax))

Other names

venetoclax-dihydroartemisinin conjugate A21